mice or rats 6, 7 . Rivetti di Val Cervo et al. 1 now propose direct reprogramming in vivo in order to redirect astrocytes in the brain away from their original glial or striatal fates to become midbrain dopamine neurons.
The authors started by systematically modifying a differentiation protocol (transfection of ASCL1, LMX1A and NR4A2) previously used to reprogram fibroblasts to midbrain-like dopamine neurons. Application of this protocol to an immortal human astrocyte line generated a small proportion of cells that expressed tyrosine hydroxylase (TH), the critical enzyme in the dopamine pathway, but that did not have a neuronal phenotype. However, addition of the chromatin-remodeling cofactor ascorbic acid, TGFβ and BMP4 inhibitors (dual-SMAD inhibition), sonic hedgehog, and a GSK3β inhibitor improved the conversion to a more neuronallike dopamine phenotype (as judged by TH and β-tubulin expression), although the cells still lacked markers of neuronal maturity.
Next, NR4A2, found to be limiting, was dropped, and NEUROD1, known to improve neural reprogramming in human cells, and microRNA218, a factor in the regulation of midbrain dopamine neuron development, were added. This led to the highest proportion of midbrain-like dopamine neurons and also resulted in expression of more mature neuronal markers. However, the neurons still exhibited a relatively simple neuronal morphology and lacked the excitable properties of typical midbrain dopamine neurons.
Finally, the authors preceded the patterning protocol above with TGFβ1 and the chromatin remodeling agents valproic acid and decitabine, as chromatin remodeling has been shown to facilitate reprogramming to induced pluripotent stem cells. Although the numbers of TH + cells generated was lower with this approach, the quality of the differentiation was improved, as shown by markers of mature neurons and a midbrain-like dopamine neuronal phenotype. remarkably effective at alleviating symptoms for many years in small numbers of Parkinson's disease patients 2 . These results are proof of the therapeutic potential of cell replacement for this condition. However, fetal-tissue grafting is implausible as a widespread medical treatment, owing to the lack of standardization inherent in this cell source, as well as to ethical concerns.
The bottleneck in donor-tissue supply has stimulated exploration of pluripotent stem cells (PSCs)-both embryonic stem cells and induced pluripotent stem cells-as an alternative source of dopamine neurons for transplantation. Clinical-grade PSCs are being expanded, banked and characterized, while advances in our understanding of embryonic development have led to reliable protocols for differentiating PSCs into fetal ventral midbrain-like dopaminergic precursors capable of improving deficits in rodent models of Parkinson's disease 3, 4 . A recent single-cell RNA-seq analysis revealed that dopamine neurons derived from both mouse and human PSCs represent many, although not all, subtypes found in the fetal ventral midbrains of the two species 5 , suggesting that further work may be needed to refine differentiation protocols.
Additional Parkinson's disease has long provided an attractive target in regenerative medicine for the development of a wide array of novel gene and cell therapies ( Fig. 1) , although none yet provide a practical therapy ready for widespread adoption. One reason for the sustained interest is that conventional treatments such as dopamine-replacement drugs and deep-brain stimulation confer substantial therapeutic benefit even though they do not restore neuronal signaling in dopaminergic circuits or alter the course of the underlying disease. The lack of regulated specificity common to these approaches may explain the declining potency and side effects that often emerge with longterm use, but their relative efficacy also suggests that the demands on a cell-based therapy may be less challenging in Parkinson's disease than in diseases that affect more precisely organized point-to-point systems of the brain. n E w S A n D v i E w S So how similar were the differentiated cells to bona fide midbrain dopamine neurons? In vitro immunohistochemistry showed that their morphology was consistent with that of midbrain dopamine neurons and that they expressed a range of cellular markers typical of those cells. Analysis of gene expression revealed downregulation of glial genes, upregulation of genes characteristic of midbrain dopamine neurons and an overall profile closer to that of human fetal midbrain (at a gestational age of cells known to be capable of improving function in patients after transplantation) than of the original astrocyte line. The gene expression profiles were not identical, which could indicate that the reprogrammed cells lacked a genuine midbrain dopamine phenotype but could also reflect other factors, such as the generation of cells at different developmental stages not matching those of the fetal tissue. Application of the protocol to primary human embryonic astrocytes led to similar results, as well as improved electrophysiological data suggestive of a bona fide midbrain dopamine neuron fate.
Evidence that astrocytes in the living adult mouse brain can be converted into midbrainlike dopamine neurons came from experiments using the standard mouse model of Parkinson's disease. In this model, administration of 6-OHDA selectively destroys midbrain dopamine neurons and deprives the striatum of its normal dopaminergic input. Rivetti di Val Cervo et al. 1 induced striatal astrocytes to adopt a dopaminergic neuron-like fate using the four reprogramming genes alone, under the control of the GFAP promoter to ensure reprogramming of astrocytes only. Reprogramming striatal, rather than midbrain, astrocytes means that the induced cells are already in their target area. Although they are ectopic, this provides them with the best chance of locating appropriate targets in the striatum.
Interestingly, although the in vivo protocol lacked the additional factors required in vitro, it appeared to produce cells expressing a mature Protective genes n E w S A n D V I E w S converts cytosine to thymine on the non-target strand and co-opts the mismatch repair pathway to complete the conversion of G-C to A-T. The two original base editor studies 1,2 used different cytidine deaminases and different permutations of domains, but both designs drove high-efficiency base editing. Sequence substitutions occurred within five-base-pair windows centered at different sites relative to the target site, depending on which fusion protein was used. This spatial constraint, along with the requirement for the canonical NGG PAM sequence of Streptococcus pyogenes Cas9, limited the number of accessible genomic target sites and fell short of single-base-pair resolution.
Cell transplantation Gene transfer
Y. Kim et al. 3 have now expanded the range of sequences that can be targeted by producing base editors with different Cas9 orthologs and with engineered Cas9 variants having different PAM recognition sequences. In addition, by introducing a pair of mutations (W90Y and R126E) in the APOBEC1 deaminase domain that tempers its activity, they reduced the size of the editing window to two to three nucleotides. The ClinVar database contains around 3,400 point mutations with known or potential clinical relevance. The improved base editors of Y. Kim et al. 3 increase the proportion of these mutations that are amenable to targeting from less than a third to more than 60%. Correction of disease-related sequence variants in clinically relevant cells types in vitro, such as T cells or hematopoietic progenitor cells, and in target tissues in vivo will be important next steps toward therapeutic application of the technology.
The specificity of genome-editing technologies is a key consideration for therapeutic applications. Base editors have shown little evidence of activity at previously characterized Cas9 nuclease off-target sites 1,2 . D. Kim et al. 4 now characterize the genome-wide off-target activity of a base editor (a Cas9-APOBEC1 fusion) using a modified version of Digenome-seq, in which uracil nucleotides
The ability to mutate a specific base pair in the large genomes of higher eukaryotes is a long-standing goal in the genome engineering community. Recent interest has focused on synthetic ribonucleoproteins known as base editors 1,2 -fusions of a catalytically inactive CRISPR-Cas9 domain and a cytosine deaminase domain that enable targeted conversion of G-C base pairs to A-T base pairs. Now, five new studies in Nature Biotechnology showcase the rapid advance of the technology and its potential for wide application (Fig. 1) .
In last month's issue, Y. Kim et al. 3 reported improved base editors that begin to address some of the key limitations of the original systems 1, 2 . In this issue, D. Kim et al. 4 measure the genome-wide specificity of a Cas9-deaminase fusion and document high specificity. Papers from Shimatani et al. 5 , Zong et al. 6 , and K. Kim et al. 7 apply base editing to generate genetically engineered animals and plants, with editing efficiencies exceeding those achieved previously using nucleases and homologydirected repair. This earlier method usually relied on delivery of a programmable nuclease, such as CRISPR-Cas9, along with a donor DNA substrate to introduce the desired changes 8, 9 . In contrast, base editors avoid both double-stranded genome cleavage, with its risk of undesirable mutations, and the need for donor DNA.
Base editors combine three activities in one ribonucleoprotein: (i) targeting of a specific DNA sequence using a Cas9 nickase mutant, programmed with an appropriate guide RNA, to generate single-stranded DNA regions that are nicked on one strand, (ii) engagement of single-stranded DNA by a cytidine deaminase to change cytosine to uracil, and (iii) inhibition of endogenous base-excision activity with a uracil glycosylase inhibitor. The resulting base editor dopamine neuron fate. Slice electrophysiology confirmed their ability to reliably generate action potentials, and behavioral studies demonstrated improved function across multiple (albeit not all) behavioral tests. Thus, whether or not the cells have acquired a genuine midbrain dopamine phenotype in every detail, they are sufficiently like these neurons in the intact brain to have a significant functional impact.
The strategy of Rivetti di Val Cervo et al. 1 offers several potential advantages. First, repair in situ avoids the prohibitive costs of manufacturing clinical-grade cell therapies. Second, host astrocytes, which appear to have a regional identity, may be predisposed to produce neurons of the same regional identity after neural induction 8 . Third, this approach may enable more-uniform dispersal and better integration of dopamine neurons in the brain compared with cell transplantation. Finally, many of the tools needed for gene therapy have already been well established and validated for human use.
Previous gene therapy trials for neurodegenerative disease have used viral vectors to genetically alter striatal cells to secrete neuroactive molecules in animal models of parkinsonism 9, 10 . The two main strategies have been to introduce either enzymes (e.g., TH, AADC or GTP cyclohydrolase) that enable nondopaminergic cells to synthesize dopamine 8 or trophic factors (e.g., CNTF or GDNF) that may exert neuroprotective influences on ongoing dopaminergic degeneration 9 . However, such in vivo gene therapies do not fundamentally alter the underlying primary phenotypes of the transfected host cells; synthesis and release of the transfected molecules is essentially unregulated; and initial clinical results have not been compelling 11 .
By contrast, the present study, while using similar tools for in situ genetic modification, reprograms host astrocytes into fully functional, apparently regulated dopamine neurons. This promises a fundamentally different mechanism of disease modification, offering to actually replace dopamine neurons lost to disease and circumventing critical immunological, safety, feasibility and ethical issues of the alternative approaches (Fig. 1) .
There is every reason for confidence that, once a fully effective reprogramming protocol is established, induced dopamine neurons will function as well as transplanted fetal midbrain dopamine neurons. But it is also possible that other, as-yet-unidentified drawbacks will emerge. For example, will astrocytes in the treated brain region be depleted to an extent that disrupts local brain function? Will the induced dopamine neurons be integrated into the neural circuitry, and will they survive over the long term? Needless to say, while we are ever the optimists and are encouraged by these results, the initial report of Rivetti di Val Cervo et al. 1 is just the beginning.
